REBECCA GAMBLE: Open Payments
NPI 1245238252 · INDIANA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,288 in 73 payments from 13 companies in 2025. Trend: 2023 $1,200 · 2024 $1,480 · 2025 $1,288
Food & beverage: $1,177Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $258 |
| Otsuka America Pharmaceutical, Inc. | 11 | $172 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $168 |
| ABBVIE INC. | 11 | $136 |
| Alkermes, Inc. | 8 | $136 |
| Vanda Pharmaceuticals Inc. | 4 | $88 |
| Neurocrine BioSciences, Inc. | 5 | $85 |
| Collegium Pharmaceutical, Inc. | 3 | $67 |
| Janssen Pharmaceuticals, Inc | 3 | $60 |
| Axsome Therapeutics, Inc. | 2 | $40 |
Products named: CAPLYTA, VRAYLAR, ARISTADA, REXULTI, FANAPT, INGREZZA, UZEDY, Jornay PM.
Industry payments across PA — which companies pay providers there.
